Amphetamine oral- Alcobra

Drug Profile

Amphetamine oral- Alcobra

Alternative Names: Abuse-Deterrent, Amphetamine Immediate-Release - Alcobra; ADAIR

Latest Information Update: 11 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alcobra
  • Developer Alcobra; Capsugel
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Attention-deficit hyperactivity disorder

Most Recent Events

  • 06 Jul 2017 Capsugel has been acquired by Lonza
  • 30 May 2017 Alcobra announces intention to submit IND to US FDA for Attention-deficit hyperactivity disorder in third quarter of 2017
  • 28 Apr 2017 Alcobra plans a bioequivalence trial for attention deficit hyperactivity disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top